Active Biotech AB (ACTI.ST)
21 Apr 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Active Biotech: FDA grants Orphan Drug Designation for tasquinimod for multiple myeloma treatment
- BRIEF-Active Biotech Q4 operating loss narrows to SEK 13.5 mln
- BRIEF-Active Biotech says receives European patent for tasquinimod
- BRIEF-Active Biotech to raise SEK 55 mln via rights issue
- BRIEF-Active Biotech Q3 loss narrows